Related references
Note: Only part of the references are listed.Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Bobak Bahrami et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Filipe Mira et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept
Yen-Yi Chen et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2017)
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
Ehsan Rahimy et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema
Jennifer K. Sun et al.
DIABETES (2015)
Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies
David M. Brown et al.
OPHTHALMOLOGY (2015)
INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA
Imene Zhioua et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab
Edward H. Wood et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2015)
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
Laurence S. Lim et al.
CLINICAL OPHTHALMOLOGY (2015)
Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia
Kyle Kovacs et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)
Preservation of the Photoreceptor Layer Following Subthreshold Laser Treatment for Diabetic Macular Edema as Demonstrated by SD-OCT
Uri Soiberman et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema 24-Month Data: Report 3
Ranjan Rajendram et al.
ARCHIVES OF OPHTHALMOLOGY (2012)
Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Joanne W. Y. Yau et al.
DIABETES CARE (2012)
Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2012)
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman et al.
OPHTHALMOLOGY (2010)
TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Farzin Forooghian et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?
Shlomit Schaal et al.
OPHTHALMOLOGY (2008)
Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES)
Lihteh Wu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2008)
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
Ingrid U. Scott et al.
OPHTHALMOLOGY (2007)
Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy
N. Miyamoto et al.
DIABETOLOGIA (2007)
Diabetic retinopathy
RN Frank
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular endothelial growth factors and angiogenesis in eye disease
AN Witmer et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2003)
Share Paper
